✦ LIBER ✦

Cetuximab (CTX) Plus Platinum-Based Chemotherapy (CT) in Recurrent and Metastatic Head-and-Neck Squamous Cell Carcinoma (HN SCC): Our Extreme Experience

✍ Scribed by Costa, D.; Gouveia, E.; Mouta, J.; Winckler, P.; Esteves, S.; Sargento, I.; Ferreira, M.; Moreira, A.

Book ID: 122160390
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 51 KB
Volume: 88
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2013.11.146

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cetuximab-based Therapy in Recurrent/Met

Cetuximab-based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Experience From an Area in Which Betel Nut Chewing Is Popular

✍ Peter Mu-Hsin Chang; Yao-Yu Hsieh; Ming-Huang Chen; Cheng-Hwai Tzeng; Pen-Yuan C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 Chinese ⚖ 198 KB

Overview of the efficacy of cetuximab in

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

✍ Jan. B. Vermorken; Roy S. Herbst; Xavier Leon; Nadia Amellal; Jose Baselga 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

## Abstract ## BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The activity of cetuximab was compared with that of commonly used treatments in this setting. ## METHODS. All

5501 ORAL Cetuximab plus platinum-based

5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)

✍ Vermorken, J.B.; Hitt, R.; Geoffrois, L.; Erfan, J.; Kawecki, A.; Zabolotnyy, D. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Impact of tumor HPV status on outcome in

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

✍ Vermorken, J. B.; Psyrri, A.; Mesia, R.; Peyrade, F.; Beier, F.; de Blas, B.; Ce 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 176 KB

Zalutumumab plus best supportive care ve

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

✍ Jean-Pascal Machiels; Somasundaram Subramanian; Agnes Ruzsa; Gabor Repassy; Igor 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 315 KB